Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

NasdaqGM - Nasdaq Real Time Price USD

ANI Pharmaceuticals, Inc. (ANIP)

Compare

57.94

-1.73

(-2.90%)

At close: February 21 at 4:00:02 PM EST

57.94

0.00

(0.00%)

After hours: February 21 at 4:20:00 PM EST

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Viatris (NASDAQ:VTRS).

StockStory 2 days ago

VTRS

ANIP
-2.90%
AMPH
-0.06%
ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates’ 46th Annual Institutional Investors ConferenceTuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare ConferenceTuesday, March 11, 2025, at 3:40pm ET The live a

GlobeNewswire 3 days ago

ANIP
-2.90%
Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q3, starting with Amneal (NASDAQ:AMRX).

StockStory 4 days ago

ANIP
-2.90%
VTRS

AMPH
-0.06%
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as

GlobeNewswire 4 days ago

ANIP
-2.90%
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 5 days ago

ANIP
-2.90%
GILD
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and Doximity (DOCS) have performed compared to their sector so far this year.

Zacks 5 days ago

ANIP
-2.90%
DOCS
Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks 5 days ago

GILD

ANIP
-2.90%
Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the now-completed Q3 generic pharmaceuticals earnings season.

StockStory 9 days ago

AMPH
-0.06%
ANIP
-2.90%
VTRS
ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.

StockStory 10 days ago

ANIP
-2.90%
VTRS

AMPH
-0.06%
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 22 days ago

ANIP
-2.90%
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

Zacks 22 days ago

ANIP
-2.90%
CGON
Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 53% gain

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at...

Simply Wall St. 23 days ago

ANIP
-2.90%
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows: Date:Wednesday, February 5, 2025Time:2:00pm ESTWebcast:Click here The live and archived webcast will be accessible from the Company’s website at www.anipharmaceuticals.com

GlobeNewswire 25 days ago

ANIP
-2.90%
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

ANIP
-2.90%
Alcami Announces CEO Transition

Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran.

PR Newswire last month

ANIP
-2.90%
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31, 2024, based on

GlobeNewswire last month

ANIP
-2.90%
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. "We are delighted to build momentum early in 2025 with the approval of the first generic for Motegr

GlobeNewswire last month

ANIP
-2.90%
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Zacks last month

ANIP
-2.90%
ADPT
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco. The live and archived webcast will be accessible from the Company’s website at www.ani

GlobeNewswire last month

ANIP
-2.90%
All You Need to Know About ANI (ANIP) Rating Upgrade to Buy

ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

ANIP
-2.90%

Performance Overview

Return	ANIP	S&P 500
YTD	+4.81%	+2.24%
1-Year	+0.54%	+20.70%
3-Year	+54.88%	+38.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ANI Pharmaceuticals, Inc. (ANIP)

Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks

ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March

Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks

ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group

Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now?

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Investing in ANI Pharmaceuticals (NASDAQ:ANIP) three years ago would have delivered you a 53% gain

ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference

Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now?

Alcami Announces CEO Transition

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

All You Need to Know About ANI (ANIP) Rating Upgrade to Buy

Performance Overview